ArriVent BioPharma, Inc. AVBP Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s retained earnings?
- ArriVent BioPharma, Inc. (AVBP) reported retained earnings of -$447.96M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s retained earnings changed year-over-year?
- ArriVent BioPharma, Inc.'s retained earnings decreased by 48.0% year-over-year, from -$302.72M to -$447.96M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s retained earnings?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s retained earnings has grown at a 60.1% compound annual growth rate (CAGR), from -$157.85M to -$404.64M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.